About astellas pharma inc. - ALPMY
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
ALPMY At a Glance
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho
Tokyo, Tokyo 103-8411
| Phone | 81-3-3244-3000 | Revenue | 11.09B | |
| Industry | Pharmaceuticals: Major | Net Income | 117.88M | |
| Sector | Health Technology | Employees | 14,754 | |
| Fiscal Year-end | 03 / 2025 | |||
| View SEC Filings |
ALPMY Valuation
| P/E Current | 51.212 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 163.425 |
| Price to Sales Ratio | 1.742 |
| Price to Book Ratio | 1.826 |
| Price to Cash Flow Ratio | 15.41 |
| Enterprise Value to EBITDA | 10.224 |
| Enterprise Value to Sales | 2.142 |
| Total Debt to Enterprise Value | 0.28 |
ALPMY Efficiency
| Revenue/Employee | 751,675.772 |
| Income Per Employee | 7,989.36 |
| Receivables Turnover | 3.063 |
| Total Asset Turnover | 0.528 |
ALPMY Liquidity
| Current Ratio | 0.929 |
| Quick Ratio | 0.736 |
| Cash Ratio | 0.261 |
ALPMY Profitability
| Gross Margin | 75.599 |
| Operating Margin | 11.104 |
| Pretax Margin | 1.754 |
| Net Margin | 1.063 |
| Return on Assets | 0.561 |
| Return on Equity | 1.078 |
| Return on Total Capital | 0.686 |
| Return on Invested Capital | 0.902 |
ALPMY Capital Structure
| Total Debt to Total Equity | 63.015 |
| Total Debt to Total Capital | 38.656 |
| Total Debt to Total Assets | 28.174 |
| Long-Term Debt to Equity | 32.487 |
| Long-Term Debt to Total Capital | 19.929 |